Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI).

C. diff causes nearly 30,000 deaths each year in the US, says Ferring, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.

Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upgrading its current co-marketing ...